PIN21 COST-EFFECTIVENESS OF INFLUENZA VACCINATION FOR HEALTHY ADULTS IN THE NETHERLANDS  by Meijboom, MJ et al.
tivity analysis indicate that brivudine is a cost-effective treatment
for HZ when it is compared to aciclovir in the Spanish setting.
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OBJECTIVES: In considering the inclusion of healthy adults
aged 50–64 in the yearly inﬂuenza vaccination scheme, the Dutch
ministry of health had issued a study on the balance of costs and
effects of vaccination compared to no vaccination, as well as the
budget impact. METHODS: An available decision model was
adapted to assess the cost-effectiveness of inﬂuenza vaccination
for healthy adults assuming average inﬂuenza epidemic severity.
Excess cardiovascular complications leading to hospital admis-
sions were accounted for. Both the peri-season and the summer
were used as reference period to estimate the (excess) disease
incidence and the inﬂuenza related complications. Direct medical
costs as well as losses in productivity were accounted for.
RESULTS: When using the peri-seasonal period as the reference
period, the discounted incremental cost-effectiveness ratio
(iCER) was €28.019 per life year saved. For the subgroup analy-
ses 50–54, 55–59 and 60–64 the iCERs were estimated at
€44.558; €37.632 and €15.810 per life year saved. The net
budget impact following an expansion of the vaccination
program with healthy adults 50-was estimated at 18 million
euros annually. In case the summer would be used as the refer-
ence period, the discounted iCER was €9.421 per life year saved.
For the subgroup analyses 50–54, 55–59 and 60–64 the iCER
were estimated at €19.036; €11.151 and €4.314 per life year
saved. The net budget impact following would amount to 12.9
million euros annually. CONCLUSION: The iCER depended on
the reference period chosen in the analyses. Subsequent policy
decisions making could as a result lead to different outcomes.
Based on the most conservative estimates, the iCER fell below
€20.000 per life year gained only for healthy adults aged 60–65.
With the summer as reference period, the entire age cohort 50–64
fell below €20,000 per life year gained.
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OBJECTIVES: Develop a multinational, cross-sectional pneumo-
coccal disease health state model to examine the expected out-
comes, costs, and incremental cost-effectiveness ratio (ICER)
among children vaccinated with PCV7 and unvaccinated adults.
METHODS: A cost-effectiveness analysis was performed to
compare costs and outcomes attributable to invasive pneumo-
coccal disease (IPD) and non-IPD for vaccinated and unvacci-
nated birth cohorts in each country/region studied. The model
also accounted for indirect (herd immunity) effects among
unvaccinated adults using country/region-speciﬁc assumptions
and estimates, which included taking a conservative approach
excluding indirect effects on pneumonia in the US and Latin
America. The following disease states were modeled: meningitis,
bacteremia, inpatient pneumonia, outpatient pneumonia, and in
children only, otitis media (both mild and moderate/severe).
Country-speciﬁc estimates for population data, incidence rates,
serotype coverage and replacement, mortality rates, vaccine efﬁ-
cacy rates, direct medical and non-medical and indirect costs
were derived from the literature and previously conducted health
economic assessments of PCV7 to populate the economic model.
Additionally, an analysis was conducted using recently published
US data on reduction of pneumonia hospitalizations and otitis
media visits following the availability of PCV7. RESULTS: The
societal ICER in the US was $111,266/life year gained (LYG)
when only considering direct effects, which decreased to $4,226/
LYG after including indirect effects. Incorporating the new data
on otitis media and pneumonia decreased the direct effects only
ICER to $13,614/LYG and was cost saving when indirect effects
were included. For other countries, the societal ICERs account-
ing for indirect effects were 21,799 CAD/LYG in Canada, 72,505
SFr/LYG in Switzerland, and $6,971/LYG in Latin America.
CONCLUSION: Vaccination with PCV7 is cost-effective in all of
the countries studied when accounting for indirect effects among
adults. Furthermore, PCV7 is cost saving among the US popula-
tion when incorporating recent data on pneumonia and otitis
media.
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OBJECTIVES: Introduction of a quadrivalent human papilloma-
virus (HPV-types 6, 11, 16, 18) vaccine is expected to signiﬁ-
cantly reduce the burden of cervical cancer (CC), cervical lesions
(CIN), genital warts (GW) and other HPV-related diseases. The
objective of this study is to assess the health and economic impact
in Belgium of implementing a quadrivalent HPV vaccination
programme alongside screening practices versus screening alone.
METHODS: A Markov model, developed to examine the epide-
miological and economic impact of a universal HPV vaccination,
was adapted to the Belgian situation, reﬂecting the local screen-
ing and treatment pathways and local epidemiological and cost
data. A lifetime horizon was applied. A vaccine that would
prevent 100% of HPV 6,11,16, and 18-associated disease, with
lifetime efﬁcacy duration, 80% coverage and costing 441.63€ per
vaccination course, given to girls at age 12 in conjunction with
current screening, was compared to screening alone. For this
analysis, 35% of CIN1, 55% of CIN2/3, 75% of CC, and 90%
of GW were considered attributable to HPV types 6, 11, 16, and
18. The model adopted the perspective of the Belgian Health
Care Payer. Robustness of results to key parameters was explored
through a series of one-way sensitivity analyses. RESULTS:
Introduction of vaccination with a quadrivalent HPV vaccine
alongside current screening practices is expected to further
reduce the lifetime risk of cervical cancer of almost 50%. Vacci-
nation alongside the current screening programme is associated
with an incremental cost-effectiveness ratio of €13,756/LYG and
€10,546/QALY. This is within the accepted range of cost-effective
interventions in Europe. Results were most sensitive to discount
rate and efﬁcacy duration but, even in the worst case, ratios were
still under €50,000/QALY. CONCLUSION: These analyses
suggest that adding a quadrivalent HPV vaccine to the current
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